U.S. Health Care REITs Stock News

NYSE:FOUR
NYSE:FOURDiversified Financial

Shift4 Payments (FOUR) Margin Squeeze And Q1 Loss Test High Growth Narratives

Shift4 Payments (FOUR) opened Q1 2026 with total revenue of US$1.1 billion and a small net loss of US$1 million, translating into basic EPS of about US$0.01 loss. Trailing 12 month revenue sat at US$4.5 billion and net income at US$62 million. Over recent quarters, revenue has moved from US$848.3 million in Q1 2025 to US$1.1 billion in Q1 2026 as quarterly EPS shifted from US$0.24 to a slight loss. This sets up a story where top line scale is meeting tighter margins. With earnings forecasts...
NasdaqGS:EMBC
NasdaqGS:EMBCMedical Equipment

Embecta (EMBC) Is Down 60.7% After Dividend Cut And Buyback Shift - What's Changed

In early May 2026, Embecta Corp. reported a year-over-year drop in quarterly sales to US$221.8 million and swung from a net income of US$23.5 million to a net loss of US$4.1 million, while also slashing its quarterly dividend to US$0.01 per share and authorizing a three-year, US$100 million share repurchase program. The combination of weaker Q2 results, lowered full-year guidance, a sharply reduced dividend, and the planned Owen Mumford acquisition highlights how Embecta is reshaping its...
NasdaqGS:DASH
NasdaqGS:DASHHospitality

DoorDash (DASH) Q1 Net Margin At 6.3% Tests Bullish Profitability Narrative

Q1 2026 results set the scene DoorDash (DASH) opened 2026 with Q1 revenue of US$4.0 billion and basic EPS of US$0.42, setting a clear benchmark for how the business is currently converting its scale into per share profitability. The company has seen quarterly revenue move from US$2.9 billion in Q4 2024 to US$3.0 billion in Q1 2025 and then to US$4.0 billion in Q1 2026, while basic EPS over the same period went from US$0.34 to US$0.46 and then US$0.42, giving investors a clean view of how...
NYSE:LNG
NYSE:LNGOil and Gas

Cheniere Energy Q1 Loss Of US$3.5b Tests Bullish Contract Stability Narrative

Cheniere Energy (LNG) opened Q1 2026 with revenue of US$5.9b and a basic EPS loss of US$16.64, compared with Q1 2025 revenue of US$5.4b and basic EPS of US$1.57. Trailing twelve month EPS sits at US$6.75 on revenue of US$19.9b. Over the last few quarters, revenue has moved from US$4.5b in Q4 2024 to US$5.0b in Q4 2025 and EPS has ranged from US$4.35 to US$10.72 before this latest quarterly loss. This leaves investors weighing a fuller year of positive EPS against a tough quarter for margins...
NasdaqGS:CLOV
NasdaqGS:CLOVHealthcare

Clover Health (CLOV) Quarterly Profit Challenges Longstanding Bearish Loss Narratives

Clover Health Investments (CLOV) opened Q1 2026 with revenue of US$749.2 million and basic EPS of US$0.05, alongside net income excluding extra items of US$27.3 million, giving investors a clean read on the core business. Over the last five reported quarters, revenue has moved from US$336.9 million in Q4 2024 to US$749.2 million in Q1 2026, while quarterly basic EPS has shifted from a loss of US$0.04 to a profit of US$0.05. This sets up this update as a key check on whether those improving...
NYSE:COR
NYSE:CORHealthcare

Cencora (COR) Q2 2026 EPS Surge Tests Bullish Earnings Growth Narratives

Cencora (COR) has put up a busy Q2 2026, with revenue of about US$78.4b, basic EPS of US$8.44 and net income of US$1,641.3m setting the tone for this earnings season update. Over the past six reported quarters, revenue has moved between roughly US$75.5b and US$86.0b while quarterly EPS has ranged from a loss of US$1.75 to a high of US$8.44. This gives investors a clear view of how the earnings line has tracked alongside a very large top line. Taken together with trailing twelve month EPS of...